ERRATUM

Erratum to: Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

Peter Joseph Jongen^{1,2}

Published online: 7 July 2017
© Springer International Publishing AG 2017

Erratum to: CNS Drugs DOI 10.1007/s40263-017-0444-x

An Online First version of this article was made available online at <http://link.springer.com/journal/40263/online/First/page/1> on 12 June 2017. A number of errors were subsequently identified in the article, and the following corrections should be noted:

Page 2, column 1, line 8: The text, which previously read:

“... INFβ-1b, pegylated INFβ-1a ...” should read:
“... IFNβ-1b, pegylated IFNβ-1a ...”

Page 6, Table 2, ‘Outcome’ column, line 1: The text, which previously read:

“... LMSQOL score ...” should read:

“... LMSQoL score ...”

Page 9, column 1, line 3: The text, which previously read:

“... INFβ-1a ...” should read:
“... IFNβ-1a ...”

Page 11, column 2, line 11: The text, which previously read:

“... INFβ ...” should read:
“... IFNβ ...”

Page 11, column 2, line 20: The text, which previously read:

“... INFβ-1a ...” should read:
“... IFNβ-1a ...”

The online version of the original article can be found under doi:[10.1007/s40263-017-0444-x](https://doi.org/10.1007/s40263-017-0444-x).

✉ Peter Joseph Jongen
p.j.h.jongen@rug.nl

¹ Department of Community and Occupational Medicine, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

² MS4 Research Institute, Ubbergseweg 34, 6522 KJ Nijmegen, The Netherlands